Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

BACKGROUND: The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. Therefore, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Park, Jonghoon, Park, Eok, Jung, Cheol-Kyu, Kang, Seung-Wan, Kim, Byung Gyu, Jung, Youngjoo, Kim, Tae Hun, Lim, Ji-Young, Lee, Sung-Eun, Min, Chang-Ki, Won, Kwang-Ai
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4806471/
https://ncbi.nlm.nih.gov/pubmed/27012957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2285-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados